

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Antengene Corporation Limited

德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

VOLUNTARY ANNOUNCEMENT

SELINEXOR (XPOVIO®), ANTENGENE'S FIRST-IN-CLASS NEW DRUG, SUCCESSFULLY INCLUDED IN 2023 NATIONAL REIMBURSEMENT DRUG LIST

This announcement is made by Antengene Corporation Limited (the “**Company**”) on a voluntary basis to provide the shareholders and potential investors of the Company with the latest business updates of the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company’s first-in-class new drug, selinexor (trade name: XPOVIO®), has been successfully included in the 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (“**2023 NRDL**”), with the scope of coverage being “limited to adult patients with relapsed and/or refractory multiple myeloma who have received prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody”. The 2023 NRDL will officially come into effect on January 1, 2024.

XPOVIO® was approved for marketing in China in December 2021. XPOVIO® is the world’s first and only orally-available, selective inhibitor of the nuclear export protein XPO1 that has obtained approval for marketing. Inclusion in the 2023 NRDL will further improve the accessibility and affordability of XPOVIO® to address the unmet medical needs of more patients with relapsed and/or refractory multiple myeloma.

This is a voluntary announcement made by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By the order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, December 14, 2023

As at the date of this announcement, the Board comprises Dr. Jay Mei, Mr. John F. Chin and Mr. Donald A. Lung as executive Directors; Dr. Kan Chen as a non-executive Director; and Ms. Jing Qian, Mr. Sheng Tang and Dr. Rafael Fonseca as independent non-executive Directors.

About XPOVIO® (selinexor)

XPOVIO® is the world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1. It offers a novel mechanism of action, synergistic effects in combination regimens, fast onset of action, and durable responses. By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the intranuclear accumulation of tumor suppressor proteins; 2) reducing the level of oncogenic proteins in the cytoplasm by inducing the intranuclear accumulation of oncogenic mRNAs; and 3) restoring hormone sensitivity by activating the glucocorticoid receptors (GR) pathway. To utilize its unique mechanism of actions, XPOVIO® is being evaluated for use in multiple combination regimens in a range of indications. At present, Antengene is conducting 8 clinical studies of XPOVIO® in mainland China for the treatment of relapsed/refractory hematologic malignancies and solid tumors (3 of these studies are being jointly conducted by Antengene and Karyopharm Therapeutics Inc. Nasdaq: KPTI).

About Antengene

Antengene Corporation Limited (“**Antengene**”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of “Treating Patients Beyond Borders”.

Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and APAC, and submitted 10 new drug applications (NDAs) in multiple APAC markets, with the NDA for XPOVIO® (selinexor) already approved in mainland China, Taiwan China, Hong Kong China, South Korea, Singapore, Australia and Macau China.

Forward-looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for year ended December 31, 2022, and the documents subsequently submitted to the Hong Kong Stock Exchange.